Key Drivers
- Strong cash generation
- High net leverage
- Rich valuation multiples
AIAI Summary
Thermo Fisher has become a structurally stronger, more resilient consumables-and-services platform with material upside from AI/lab‑automation, but its premium valuation now makes the investment conditional on clear execution of recent M&A/AI initiatives and visible deleveraging (watch guidance, integration KPIs, and a reclaim of ~500 with improving volume as triggers); remain selective—buy on confirmed synergy-driven margin recovery or meaningful multiple compression, otherwise avoid for passive long-term allocation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash generation
- •High net leverage
- •Rich valuation multiples
Thermo Fisher delivers strong margins, ROIC and free cash flow that support returns, but elevated debt, large intangibles and rich multiples warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Falling momentum
- •Near-term support
- •Supply at resistance
Short-term downtrend with ~7% decline over the last month, testing support around $464–$470 while facing supply into the $500–$520 resistance band.
Price dropped from $510.43 to $474.39 (~7%) over the last month, tightening ranges and increasing breakout potential
Sentiment & News
Key News Insights:
- •Durable demand
- •Clario acquisition
- •Cautious guidance
Thermo Fisher shows durable pharma/diagnostics demand and active M&A (Clario) but faces near‑term headwinds—currency, competition and cautious FY26 guidance—amid a ~20% YTD share pullback. #M&A
M&A and consumables strength support long‑term upside, but near‑term share performance will likely remain muted until guidance visibility and macro/currency risks ease
Similar Companies in Healthcare
Other companies in the same sector with AI ratings